TPU-0037-A, B, C and D, Novel Lydicamycin Congeners with Anti-MRSA Activity from Streptomyces platensis TP-A0598.

Furumai, Tamotsu; Eto, Keitaro; Sasaki, Tetsuhiko; Higuchi, Hiroko; Onaka, Hiroyasu; Saito, Noriko; Fujita, Takeshi; Naoki, Hideo; Igarashi, Yasuhiro

doi:10.7164/antibiotics.55.873

Cited by 46 publications

(40 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, anti-MRSA compounds such as marinopyrroles A and B from Streptomyces sp. CNQ-418 (MIC= ≤ 2 μM) (Hughes et al, 2008), MC21A and MC21B from Pseudoalteromonas phenolica (MIC=1-2 to 1-4 μg/mL) (Isnansetyo et al, 2003;Isnansetyo and Kamei, 2009), abyssomicin C from Verrucosispora AB-18-032 (MIC = 4 to 13 μg/mL) (Bister et al, 2004;Keller et al, 2007), lydicamycin from Streptomyces lydicus (MIC 6 μg/mL) (Furumai et al, 2002), and so on. Similarly, BE-43472B from Streptomyces sp.…”

Section: Resultsmentioning

confidence: 99%

Manumycin from a new Streptomyces strain shows antagonistic effect against methicillin-resistant Staphylococcus aureus (MRSA)/vancomycin-resistant enterococci (VRE) strains from Korean Hospitals

Choi¹,

Cho²,

Simkhada³

et al. 2013

Afr. J. Biotechnol.

View full text Add to dashboard Cite

An antimicrobial compound, highly effective against multidrug-resistant (MDR) bacteria, purified from a Streptomyces strain was identified as manumycin. The minimal inhibitory concentrations (MICs) of manumycin against 8 different strains of methicillin-resistant Staphylococcus aureus (MRSA) were ranged 2 to 32 μg/ml. Similarly, MICs of manumycin against 4 vancomycin-resistant enterococci (VRE) strains were ranged 8 to 32 μg/ml while it remained ineffective against 4 other VRE strains. Compared to vancomycin, manumycin provided slightly weaker activity against MRSA strains but stronger activity against 4 VRE strains. This is the first report of antagonistic effect of manumycin against MDR pathogens.

show abstract

Section: Resultsmentioning

confidence: 99%

Manumycin from a new Streptomyces strain shows antagonistic effect against methicillin-resistant Staphylococcus aureus (MRSA)/vancomycin-resistant enterococci (VRE) strains from Korean Hospitals

Choi¹,

Cho²,

Simkhada³

et al. 2013

Afr. J. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…The fermentation broth of a marine actinomycete Streptomyces platensis (TP-A0598) provided lydicamycin (57) and four new analogues, TPU-0037 A-D (58-61) possessing octahydrodecalin skeletons [57]. The lydicamycins (57-61) showed significant bioactivity against five Gram-positive bacteria (including MRSA), with MIC values in the range of 0.39-12.5 µg/mL [57,58]. Among them, molecule 60 displayed the most potent bioactivity, while 59 showed the lowest level of bioactivity, indicating that the C14-C15 olefin may diminish antibacterial activity [57].…”

Section: -Decalinoyltetramic Acidsmentioning

confidence: 99%

The Biological and Chemical Diversity of Tetramic Acid Compounds from Marine-Derived Microorganisms

Jiang

Chen

et al. 2020

Marine Drugs

View full text Add to dashboard Cite

Tetramic acid (pyrrolidine-2,4-dione) compounds, isolated from a variety of marine and terrestrial organisms, have attracted considerable attention for their diverse, challenging structural complexity and promising bioactivities. In the past decade, marine-derived microorganisms have become great repositories of novel tetramic acids. Here, we discuss the biological activities of 277 tetramic acids of eight classifications (simple 3-acyl tetramic acids, 3-oligoenoyltetramic acids, 3-decalinoyltetramic acid, 3-spirotetramic acids, macrocyclic tetramic acids, N-acylated tetramic acids, α-cyclopiazonic acid-type tetramic acids, and other tetramic acids) from marine-derived microbes, including fungi, actinobacteria, bacteria, and cyanobacteria, as reported in 195 research studies up to 2019.

show abstract

“…Whole cell hydrolysates contain LL-diaminopimelic acid, glucose, mannose, xylose and ribose [9,10]. Sequence data of the full length 16S rDNA [11] indicates 97.42% identity to Streptomyces thermoviolaceus. On the basis of these morphological and chemical characteristics, the strain TP-A0648 was identified as Streptomyces sp.…”

Section: Taxonomy Of the Producing Strainmentioning

confidence: 99%

Anicemycin, a New Inhibitor of Anchorage-independent Growth of Tumor Cells from Streptomyces sp. TP-A0648

et al. 2005

Self Cite

View full text Add to dashboard Cite

The anchorage-independence of cells is closely related to their tumorigenicity. In the screening of inhibitors of anchorage-independent growth of tumor cells, anicemycin was isolated from the fermentation broth of an actinomycete strain TP-A0648. The producing strain was isolated from a leaf of Aucuba japonica collected in Toyama, Japan and identified as Streptomyces sp. based on the taxonomic data. The structure of anicemycin was elucidated as a new analog of spicamycin by NMR and MS analysis. Anicemycin inhibited the anchorage-independent growth of the human ovary cancer SKOV-3 cells with an IC 50 of 0.015 mM about three times more potently than their anchorage-dependent growth.Keywords anicemycin, anchorage-independent growth, cytotoxic, spicamycin, Streptomyces IntroductionMost of the previously developed antitumor agents act mainly on the nucleic acid biosynthesis, DNA or microtubules and therefore these agents show cytotoxicity to normal tissues with significant adverse effects. Recent researches on the mechanism of cancer have been disclosing that a number of oncogenes are involved in tumorigenesis and many of these gene products are functioning as signal transduction molecules. The agents that inhibit the signal transduction of oncogenes are expected to become selective and safe anticancer drugs [1].The normal cells derived from epithelial and endothelial cells can proliferate only when they attach to the firm substrate. When these cells detach from the substrate and lose contact with the matrix, they die in an apoptotic process termed 'anoikis'. On the other hand, cancer cells usually have developed resistance to anoikis and show growth ability without the firm substrate attachment, namely the anchorage-independence. Cell viability under anchorage-dependent conditions is regulated by integrin signal transduction through its interaction with the extracellular matrix. Various oncogenes expressed in transformed and cancer cells cause constitutive activation of the integrin signaling pathway which results in anoikis resistance [2,3].In our screening program of new antitumor compounds from microbial secondary metabolites, anicemycin (Fig. 1) was isolated as an inhibitor of anchorage-independent growth from Streptomyces sp. TP-A0648. In this paper, we describe the fermentation, isolation, structure and biological activity of anicemycin. Materials and Methods General Experimental ProceduresNMR experiments were performed on a JEOL JNM-LA400 NMR spectrometer. The MS spectra were measured on a JEOL JMS-HX110A spectrometer. UV spectra were

show abstract

TPU-0037-A, B, C and D, Novel Lydicamycin Congeners with Anti-MRSA Activity from Streptomyces platensis TP-A0598.

Cited by 46 publications

References 12 publications

Manumycin from a new Streptomyces strain shows antagonistic effect against methicillin-resistant Staphylococcus aureus (MRSA)/vancomycin-resistant enterococci (VRE) strains from Korean Hospitals

Manumycin from a new Streptomyces strain shows antagonistic effect against methicillin-resistant Staphylococcus aureus (MRSA)/vancomycin-resistant enterococci (VRE) strains from Korean Hospitals

The Biological and Chemical Diversity of Tetramic Acid Compounds from Marine-Derived Microorganisms

Anicemycin, a New Inhibitor of Anchorage-independent Growth of Tumor Cells from Streptomyces sp. TP-A0648

Contact Info

Product

Resources

About